Efficacy, Safety and Tolerability of AZD6234 in Participants Living with Overweight or Obesity with Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Trial Identifier: D8750C00005
Sponsor: AstraZeneca
Start Date: March 2025
Primary Completion Date: January 2026
Study Completion Date: January 2026
Condition: Obesity

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AL Birmingham, AL, US, 35205
US, AL Mobile, AL, US, 36608
US, FL Doral, FL, US, 33166
US, FL Jacksonville, FL, US, 32216
US, FL Miami, FL, US, 33135
US, FL Winter Park, FL, US, 32789
US, GA Canton, GA, US, 30114
US, IL Chicago, IL, US, 60640
US, IL Oak Brook, IL, US, 60523
US, KS Newton, KS, US, 67114
US, KY Lexington, KY, US, 40509
US, MO Kansas City, MO, US, 64114
US, NV Las Vegas, NV, US, 89119
US, OK Norman, OK, US, 73069
US, TX San Antonio, TX, US, 78229